Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (Weighted Average) (2019 - 2025)

Eton Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $26.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 4.18% year-over-year to $26.9 million; the TTM value through Sep 2025 reached $26.9 million, up 4.18%, while the annual FY2024 figure was $25.9 million, 0.97% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $26.9 million at Eton Pharmaceuticals, roughly flat from $26.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $26.9 million in Q2 2025 and bottomed at $25133.0 in Q2 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $25.2 million (2021), against an average of $20.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 99.9% in 2023 before it surged 100832.42% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $25.2 million in 2021, then decreased by 0.24% to $25.1 million in 2022, then increased by 1.99% to $25.6 million in 2023, then rose by 0.97% to $25.9 million in 2024, then increased by 3.85% to $26.9 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Shares Outstanding (Weighted Average) are $26.9 million (Q3 2025), $26.9 million (Q2 2025), and $26.9 million (Q1 2025).